Compare FRAF & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | BNR |
|---|---|---|
| Founded | 1906 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.8M | 252.7M |
| IPO Year | 1995 | 2019 |
| Metric | FRAF | BNR |
|---|---|---|
| Price | $58.45 | $16.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 29.7K | 18.8K |
| Earning Date | 04-23-2026 | 06-05-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 88.84 | N/A |
| EPS | ★ 4.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.44 | $111.65 |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $12.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.44 | $2.49 |
| 52 Week High | $60.00 | $41.72 |
| Indicator | FRAF | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 60.25 | 41.59 |
| Support Level | $45.02 | $15.57 |
| Resistance Level | $60.00 | $23.19 |
| Average True Range (ATR) | 1.90 | 1.27 |
| MACD | -0.08 | -0.14 |
| Stochastic Oscillator | 69.98 | 24.83 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.